S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
“The Bull Market Is Officially OVER”  (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
“The Bull Market Is Officially OVER”  (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
“The Bull Market Is Officially OVER”  (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
“The Bull Market Is Officially OVER”  (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
“The Bull Market Is Officially OVER”  (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
“The Bull Market Is Officially OVER”  (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
“The Bull Market Is Officially OVER”  (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
“The Bull Market Is Officially OVER”  (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:DMAC

DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

$1.19
-0.01 (-0.83%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.18
$1.20
50-Day Range
$1.13
$1.54
52-Week Range
$1.12
$4.01
Volume
36,105 shs
Average Volume
81,176 shs
Market Capitalization
$31.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

DiaMedica Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
740.3% Upside
$10.00 Price Target
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of DiaMedica Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$24,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.53) to ($0.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

225th out of 1,043 stocks

Pharmaceutical Preparations Industry

89th out of 510 stocks

DMAC stock logo

About DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Stock News Headlines

DiaMedica: What's Happened And What's The Value Here
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
DiaMedica Therapeutics Inc DMAC Stock Chart
DiaMedica Therapeutics Inc. (DMAC)
See More Headlines
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Company Calendar

Last Earnings
11/10/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/13/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DMAC
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+740.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-13,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.33 per share

Miscellaneous

Free Float
24,962,000
Market Cap
$31.47 million
Optionable
Not Optionable
Beta
1.99

Key Executives

  • Mr. Dietrich John Pauls MBAMr. Dietrich John Pauls MBA (Age 51)
    Pres, CEO & Director
    Comp: $684.09k
  • Mr. Scott B. Kellen C.A. (Age 57)
    CFO & Company Sec.
    Comp: $391.72k
  • Dr. Edward G. Calamai Ph.D.
    Consulting Head of Manufacturing
  • Dr. Kirsten L. Gruis M.D. (Age 49)
    M.S., Chief Medical Officer
  • Mr. Dominic R. Cundari (Age 71)
    Chief Commercial Officer
  • Ms. Julie VanOrsdel Daves CCRP
    Sr. VP of Clinical Devel. Operations













DMAC Stock - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings
or view top-rated stocks.

What is DiaMedica Therapeutics' stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year target prices for DiaMedica Therapeutics' stock. Their DMAC share price forecasts range from $8.00 to $12.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 740.3% from the stock's current price.
View analysts price targets for DMAC
or view top-rated stocks among Wall Street analysts.

How have DMAC shares performed in 2022?

DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of the year. Since then, DMAC stock has decreased by 68.1% and is now trading at $1.19.
View the best growth stocks for 2022 here
.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 34,500 shares, a drop of 35.0% from the October 31st total of 53,100 shares. Based on an average daily volume of 56,600 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.2% of the shares of the company are short sold.
View DiaMedica Therapeutics' Short Interest
.

When is DiaMedica Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our DMAC earnings forecast
.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. During the same quarter in the previous year, the firm posted ($0.19) earnings per share.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.16%) and Citadel Advisors LLC (0.13%). Insiders that own company stock include Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends
.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $1.19.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $31.47 million. The company earns $-13,590,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.

This page (NASDAQ:DMAC) was last updated on 12/1/2022 by MarketBeat.com Staff